At a glance
- Originator Abbott Laboratories
- Class Anti-inflammatories; Antiallergics
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 30 Jan 2013 Discontinued - Preclinical for Inflammation in USA (PO)
- 07 Sep 1998 No development reported - Preclinical for Inflammation in USA (PO)
- 29 Aug 1996 Preclinical development for Inflammation in USA (PO)